Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 35.1% in November

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a significant drop in short interest in November. As of November 15th, there was short interest totalling 144,300 shares, a drop of 35.1% from the October 31st total of 222,500 shares. Currently, 3.4% of the company’s stock are sold short. Based on an average daily trading volume, of 296,000 shares, the days-to-cover ratio is presently 0.5 days.

Institutional Trading of Alzamend Neuro

A hedge fund recently bought a new stake in Alzamend Neuro stock. Virtu Financial LLC acquired a new position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned approximately 0.38% of Alzamend Neuro at the end of the most recent reporting period. 49.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets reduced their target price on shares of Alzamend Neuro from $50.00 to $35.00 and set a “buy” rating on the stock in a research report on Monday, November 11th.

Alzamend Neuro Price Performance

NASDAQ:ALZN opened at $1.27 on Friday. The firm has a 50-day moving average of $1.56 and a two-hundred day moving average of $3.09. Alzamend Neuro has a 1-year low of $1.25 and a 1-year high of $15.06.

Alzamend Neuro (NASDAQ:ALZN) last issued its quarterly earnings data on Wednesday, September 11th. The company reported ($1.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.38) by $1.13. On average, research analysts expect that Alzamend Neuro will post -14.27 EPS for the current year.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.